| Name | Title | Contact Details |
|---|
The New York Jets are a professional football team headquartered in Florham Park, New Jersey, representing the New York metropolitan area. It is a privately owned business with under 200 employees. Founded more than 50 years ago, the Jets franchise has defined itself as a trailblazer, trendsetter and leader in the regions sports landscape and across the NFL. Since Chairman and CEO Woody Johnson purchased the team in 2000, the team has undergone a major revitalization and rebranding, focused on winning both on and off the field. For Johnson, capturing the franchises second championship is priority #1. Under his ownership, the team has posted seven winning seasons, appeared in seven postseason games, including two AFC Championship Game appearances, and winning an AFC East division title in 2002. They have also made strides off the field with the opening of two state-of-the-art homes: the Atlantic Health Jets Training Center in 2008 and MetLife Stadium in 2010. Honored as one of NJ Bizs 2018 Best Places to Work in New Jersey. This award recognizes and honors New Jersey-based employers who show dedication to their employees professional growth and quality of life.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
Verdegard offers a complete suite of innovative, integrated, and concierge-level services. Plan designs include PPO options, reference-based, level funded, and hybrid plans which provide unique transparency, patient advocacy, and cost containment options to maximize the benefits and savings.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.